Show simple item record

dc.contributor.authorAkova, M.
dc.date.accessioned2019-12-10T11:20:40Z
dc.date.available2019-12-10T11:20:40Z
dc.date.issued2008
dc.identifier.issn1198-743X
dc.identifier.urihttps://doi.org/10.1111/j.1469-0691.2007.01847.x
dc.identifier.urihttp://hdl.handle.net/11655/15364
dc.description.abstractSulbactam irreversibly inhibits the hydrolytic activity of beta-lactamases. This compound is commercially available in combination with either ampicillin or cefoperazone. In each instance, the activity of the partner antibiotic against P-lactamase-producing bacteria is restored. One of the particular advantages of using sulbactam-containing combinations is that sulbactam itself has inherent activity against some Acinetobacter baumannii. Sulbactam combinations have not demonstrated strong selective pressures for extended-spectrum beta-lactamase-producing Enterobacteriaceae and vancomycin-resistant enterococci. In contrast to clavulanate, sulbactam does not induce class I (Ampc) chromosomal beta-lactamases in Enterobacteriaceae.
dc.language.isoen
dc.publisherBlackwell Publishing
dc.relation.isversionof10.1111/j.1469-0691.2007.01847.x
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectInfectious Diseases
dc.subjectMicrobiology
dc.titleSulbactam-Containing Beta-Lactamase Inhibitor Combinations
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalClinical Microbiology And Infection
dc.contributor.departmentİç Hastalıkları
dc.identifier.volume14
dc.identifier.startpage185
dc.identifier.endpage188
dc.description.indexWoS
dc.description.indexScopus


Files in this item

This item appears in the following Collection(s)

Show simple item record